文献速递生殖医学

阿托西班用于既往种植失败者冻融囊胚移植:一项随机对照试验

Atosiban in individuals with previous implantation failure undergoing frozen blastocyst transfer: a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2025-01-01

这项单中心随机双盲安慰剂对照试验纳入1100例既往一次种植失败的冻融单囊胚移植者,比较移植前30分钟静脉给予阿托西班37.5 mg与安慰剂。阿托西班组活产率49.5%(272/549),安慰剂组44.7%(246/550),差异未达统计学显著(RR 1.11,95%CI 0.98-1.26,P=0.10)。

要点

  • 既往一次种植失败者冻融囊胚移植前静脉给予阿托西班,未显著提高活产率。
  • 阿托西班组活产272/549(49.5%),安慰剂组246/550(44.7%),RR 1.11(95%CI 0.98-1.26)。
  • 异常子宫收缩亚组中两组活产率分别为51.9%与39.3%,差异未达统计学显著(P=0.11)。

核心结论

  • 在既往一次种植失败者中,冻融囊胚移植前后静脉给予阿托西班未显著提高活产率。
  • 作者表示研究结果不支持常规使用静脉阿托西班来改善冻融胚胎移植者的妊娠结局。

研究设计与样本

  • 随机、对照、单中心、安慰剂对照临床试验,受试者、治疗医生和胚胎学家对分组设盲。
  • 招募时间为2019年7月至2023年6月,随访至2024年5月。
  • 1100例既往ART中经历一次种植失败、计划单冻融囊胚移植者按1:1随机接受静脉阿托西班37.5 mg(n=549)或安慰剂(n=551),均于移植前30分钟给药。
  • 主要结局为活产;预设亚组分析按有无异常子宫收缩进行。
  • 试验在中国临床试验注册中心注册,注册号ChiCTR1900022333,注册日期2019年4月5日,首例入组日期2019年7月1日。

主要发现

  • 1100例随机参与者平均年龄31岁,1099例(99.9%)纳入主要结局评估,安慰剂组1例临床妊娠后失访。
  • 阿托西班组活产272/549(49.5%),安慰剂组活产246/550(44.7%),绝对差4.8%(95%CI -1.1至10.7),RR 1.11(95%CI 0.98至1.26),P=0.10。
  • 720例(总队列65%)接受子宫收缩力评估,其中163例(23%)存在异常收缩。
  • 异常收缩者中,阿托西班组与安慰剂组活产率分别为51.9%与39.3%,绝对差12.6%(95%CI -2.6至27.8),RR 1.32(95%CI 0.94至1.86),P=0.11。

临床怎么用

  • 作者表示研究结果不支持常规使用静脉阿托西班来改善冻融胚胎移植者的妊娠结局。

局限性

  • 单中心设计可能限制研究结果的广泛适用性。
  • 视频评估具有主观性。
  • 研究聚焦于经历胚胎种植失败的特殊人群,可能引入偏倚和混杂因素。
  • 仅65%的参与者接受了子宫收缩检查,且因资源限制未进行复查,限制了研究的分析效能及对阿托西班有效性的确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the intravenous administration of Atosiban around the time of frozen blastocyst transfer to reduce uterine contractility increase the likelihood of live birth in individuals undergoing ART treatment? SUMMARY ANSWER: In individuals with a history of one previous implantation failure, Atosiban did not significantly increase the live birth rates following frozen blastocyst transfer. WHAT IS KNOWN ALREADY: Excessive uterine contraction waves during the embryo transfer procedure have been associated with decreased pregnancy rates. Atosiban, an oxytocin receptor antagonist, could reduce uterine contractions and potentially enhance implantation success in ART. However, data are inconclusive. STUDY DESIGN, SIZE, DURATION: This study is a randomized, controlled, single-center, randomized, placebo-controlled clinical trial. Recruitment was from July 2019 to June 2023, with follow-up until May 2024. Participants, treating clinicians and embryologists were blinded to group assignment. Participants were randomized in a 1:1 ratio to receive intravenous Atosiban (37.5 mg) (n = 549) or placebo 30 min (n = 551) before the transfer procedure. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eleven hundred individuals scheduled for single frozen blastocyst transfer who had previously experienced one episode of implantation failure during ART. Uterine contractility was assessed via transvaginal ultrasound before administering the assigned intervention. The primary outcome was live birth. A pre-specified subgroup analysis was performed in individuals with and without abnormal uterine contractions. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 1100 randomized participants (mean age, 31 years), 1099 (99.9%) were assessed for the primary outcomes, with the exception of one participant in the placebo group who was lost to follow-up after clinical pregnancy. Live birth occurred in 272/549 (49.5%) in the Atosiban group and 246/550 (44.7%) in the placebo group (absolute difference 4.8%, 95% CI -1.1 to 10.7; risk ratio [RR] 1.11, 95% CI 0.98 to 1.26; P = 0.10). Uterine contractility was evaluated in 720 participants (65% of the total cohort). Among them, 163 participants (23%) with abnormal contractions had live birth rates of 51.9% and 39.3% in the Atosiban and placebo groups, respectively (absolute difference 12.6%, 95% CI -2.6 to 27.8; RR 1.32, 95% CI 0.94 to 1.86; P = 0.11). LIMITATIONS, REASONS FOR CAUTION: The study's findings may not be widely applicable due to its single-center design, subjective video assessments, and focus on a specific subset of individuals experiencing failed embryo implantation, potentially introducing biases and confounding factors. Additionally, the limited examination of uterine contractions in only 65% of participants and the absence of re-evaluation due to resource constraints restrict the study's analytical power and the confirmation of Atosiban's effectiveness. WIDER IMPLICATIONS OF THE FINDINGS: Our study shows do not support the routine use of intravenous Atosiban to improve pregnancy outcomes among individuals undergoing frozen embryo transfers. STUDY FUNDING/COMPETING INTEREST(S): Science and Technology Department of Shaanxi Province, China (2022SF-564); Innovation Team of Shaanxi Provincial Health and Reproductive Medicine Research (2023TD-04); Key Industrial Chain Projects in Shaanxi Province: Research on Assisted Reproductive Technologies and Precision Prevention System for Genetic Diseases Preconception (2023-ZDLSF-48); Northwest Women's and Children's Hospital, Xi'an, China and Ferring Pharmaceuticals (Shanghai) Company Limited. Ferring Pharmaceuticals (Shanghai) Company Limited supplied Atosiban free of charge. All funding parties had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decisions to submit the results for publication. B.W.M. reports consultancy, travel support, and research funding from Merck and consultancy for Organon and Norgine; owning stock in ObsEva; and holding an NHMRC Investigator Grant (GNT1176437). W.L. is supported by an NHMRC Investigator grant (GNT2016729). All other authors declare no competing interests. TRIAL REGISTRATION NUMBER: The RCT was registered in the Chinese Clinical Trial Registry; Study Number: ChiCTR1900022333. TRIAL REGISTRATION DATE: 5 April 2019. DATE OF FIRST PATIENT’S ENROLMENT: 1 July 2019.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cai H, Liu S, Li W, et al. Atosiban in individuals with previous implantation failure undergoing frozen blastocyst transfer: a randomized controlled trial. Hum Reprod. 2025. PMID: 40036869. doi:10.1093/humrep/deaf035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。